Still time to register! Join us this Thursday in Center City for a phenomenal, practice-changing review of everything happening in GU Oncology - and yes, a great meal too!

Doctors! Tell us YOUR answer! How should the term “cure” be used in #kidneycancer? #ESMO25 Let’s see how many responses we can get! @DrChoueiri @montypal @DrYukselUrun @TiansterZhang @Uromigos @OncoAlert

#ESMO25 starts today! Excited to present #evidencebased data from @kcCURE exploring how metastatic #kidneycancer pts interpret the word “cure.”

#KidneyCancer Patients want cures—but few believe they’re possible. Learn what patients living with metastatic RCC think about the word “cure." 📍Abstract 2636P | #ESMO25 #KidneyCancer #mRCC @TiansterZhang @spsutkaMD @DrVaishampayan @MichaelStaehler @lisapic @AlbigesL

It’s hard to believe Americas 🇺🇸 🇨🇦 3-0 down in the Uromigos Cup 🏆 . Weekly photos from each team from around the world wins points . ❤️ =points. Can the Americas 🇺🇸🇨🇦 catch up ? Here is @walterstadler5 in Chicago. @OncoAlert @montypal @crisuarez08 @DrChoueiri

Final analysis of Checkmate 9ER in @Annals_Oncology : 1L mRCC trial https://t.co/IVeJwF2r7T

I am delighted and honored to join the great team @RushUrology @RushMedical I want to thank my colleagues @UCSDHealth and @UCSD_Urology #Chicago here I come! #KidneyCancer #UrologicOncology @UroOnc @AmerUrol @EECherullo @cjkane10

Phase 2 trial: In oligometastatic clear-cell RCC, serial metastasis-directed therapy (no systemic Tx) achieved median 34 mo systemic therapy-free survival & 17.7 mo PFS with low grade 3–4 toxicity. A promising option for select pts. 🔎To finish discussion need to 3 arms phase-3

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo @PCFnews @urotoday @OncoAlert

Join Dr. Sumanta Kumar Pal (@montypal) & colleagues on Saturday, May 31, at 6:30 PM CDT/7:30 PM EDT during #ASCO25 for a #RenalCellCarcinoma #MedEd event. Produced with @KCCure. https://t.co/lJkRO9K17V #KidneyCancer #Oncology

📣 Live at #ASCO25: Learn from real-world #RCC cases with @montypal, Dr. McDermott & @TiansterZhang  ✅ IO-based regimens  ✅ Sequencing therapies  ✅ Shared decision-making  🗓️ May 31 | 7:00 PM CDT  🔗

Just a week away! Please join us in Chicago at this Peerview event, 7pm central on Sat 5/31! Register here: https://t.co/MeSV8wffTi

Great job @KidneyCancerJ! Do not miss all the research articles from Linnea Olsson, @MichaelStaehler @LauraBukavinaMD David Jin, Lars Lund. Thank you all for your contributions!!

Glimpses of #IKCSEU25!

Congratulations @MichaelStaehler, recipient of #FitzgeraldAward @KidneyCancer #IKCSEU25! Legacy and innovation. Sets challenges and vision for our field to find the right patients for the right treatments.

Good morning everyone, #IKCSEU25 begins TODAY 🎊 🎉 We are excited to come together here in Amsterdam talk about the future of #kidneycancer and how best to care for the patients who are counting on us. Looking forward to the next few days!

🎉CONGRATULATIONS to @MichaelStaehler, recipient of the KCA's 2025 John Fitzpatrick Award recognizing excellence in urology care! The award will be presented at #IKCSEU25, don't miss his lecture! https://t.co/UAzsbVfCxE

One day left for early registration to attend the 2025 IKCS: Europe! #IKCSEU25 See you in Amsterdam, May 1-3 for an exciting #kidneycancer meeting and the opportunity to network with others passionate about making a difference for patients! Register:

Global Effect of Cardiovascular Risk Factors on Lifetime Estimates: @NEJM 🥸 Great work from Germany on global life time risk of CVD risk 😱 Summary 👇👇👇

70% of health-related internet searches are zero-click - which means pts are relying on snippets and AI overviews for information. When you see something like this that is outdated, misleading, or both - click on the feedback button. It's a small way you can help improve